Menu
Menu
Eris Lifesciences vends the entire interest it holds in the deadweight of two components for Therapeutics Ltd. to Eris for Rs 861.9 crore, thus connecting up with its core business growth, which is a strategic focus.
Pfizer and Mylan have formed a strategic marketing and supply partnership for two key medications, Ativan and Pacitane. This collaboration aims to expand global access to treatments for anxiety disorders and Parkinsonism, ensuring broader availability for patients in need.
Cipla Ltd’s stock has been on a strong upward trajectory, gaining 1.46% today and 20.84% over the past year. delves into the factors driving Cipla's performance, its comparison with the broader market, and the pharmaceutical sector's outlook.
Bajaj Healthcare’s stock surged to a 52-week high after its API manufacturing facility in Vadodara, Gujarat, received approval from Australia’s Therapeutic Goods Administration (TGA). This regulatory nod opens up new opportunities in the Australian and New Zealand markets, strengthening the company's global footprint and paving the way for increased CDMO contracts. With strong financial results, Bajaj Healthcare is poised for continued growth and success in the pharmaceutical industry.
Marksans Pharma saw a 1.94% increase in its stock after receiving USFDA approval for its generic Loratadine Tablets. This approval opens new opportunities in the allergy relief market, complementing the company’s strong financial performance with a 15.8% rise in net profit for Q2 FY25.
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has secured EU GMP certification for its biosimilars manufacturing facility, a key milestone in its global expansion. This certification positions Aurobindo to bring high-quality biosimilars to the European market, with three products currently under review for approval.
Emcure Pharmaceuticals delivered impressive Q2 FY25 results, posting a 20% YoY revenue growth and a 38% surge in profit after tax. With strong performances in both domestic and international markets, driven by strategic acquisitions and new partnerships, the company is well-positioned for continued growth. Explore the key factors behind Emcure's success and its outlook for the future.
Lupin Pharmaceuticals faces a significant moment as its Pune biotech facility receives five observations from the FDA during a recent pre-approval inspection. While this poses regulatory challenges, the company continues to showcase robust financial growth, with a 76% increase in net profit. In this post, we delve into the implications of the FDA's findings, Lupin's strategies for addressing these issues, and what it means for investors and the future of its biotech products
SeQuent Scientific and Viyash Lifesciences have announced a strategic merger aimed at establishing a leadership position in the global animal health market. By combining their strengths, the two companies will enhance R&D capabilities, expand manufacturing resources, and improve service delivery, creating a robust platform for innovation and growth. This merger marks a pivotal moment in the industry, positioning the combined entity to better serve customer needs and capitalize on emerging market opportunities.
Mankind Pharma is set to raise ₹7,000 crore in debt to acquire Bharat Serums and Vaccines for ₹13,630 crore. This strategic move aims to enhance growth and profitability, leveraging Bharat Serums' strong market position. Explore the financial breakdown and implications of this significant acquisition.